These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24904334)

  • 1. Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs.
    Tannenbaum PL; Stevens J; Binns J; Savitz AT; Garson SL; Fox SV; Coleman P; Kuduk SD; Gotter AL; Marino M; Tye SJ; Uslaner JM; Winrow CJ; Renger JJ
    Front Behav Neurosci; 2014; 8():182. PubMed ID: 24904334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys.
    Tannenbaum PL; Tye SJ; Stevens J; Gotter AL; Fox SV; Savitz AT; Coleman PJ; Uslaner JM; Kuduk SD; Hargreaves R; Winrow CJ; Renger JJ
    Sleep; 2016 Mar; 39(3):603-12. PubMed ID: 26943466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats.
    Fox SV; Gotter AL; Tye SJ; Garson SL; Savitz AT; Uslaner JM; Brunner JI; Tannenbaum PL; McDonald TP; Hodgson R; Yao L; Bowlby MR; Kuduk SD; Coleman PJ; Hargreaves R; Winrow CJ; Renger JJ
    Neuropsychopharmacology; 2013 Nov; 38(12):2401-8. PubMed ID: 23722242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
    Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
    BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold.
    Gotter AL; Winrow CJ; Brunner J; Garson SL; Fox SV; Binns J; Harrell CM; Cui D; Yee KL; Stiteler M; Stevens J; Savitz A; Tannenbaum PL; Tye SJ; McDonald T; Yao L; Kuduk SD; Uslaner J; Coleman PJ; Renger JJ
    BMC Neurosci; 2013 Aug; 14():90. PubMed ID: 23981345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin Receptor Blockade-Induced Sleep Preserves the Ability to Wake in the Presence of Threat in Mice.
    Iwakawa S; Kanmura Y; Kuwaki T
    Front Behav Neurosci; 2018; 12():327. PubMed ID: 30687033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual orexin receptor antagonists show distinct effects on locomotor performance, ethanol interaction and sleep architecture relative to gamma-aminobutyric acid-A receptor modulators.
    Ramirez AD; Gotter AL; Fox SV; Tannenbaum PL; Yao L; Tye SJ; McDonald T; Brunner J; Garson SL; Reiss DR; Kuduk SD; Coleman PJ; Uslaner JM; Hodgson R; Browne SE; Renger JJ; Winrow CJ
    Front Neurosci; 2013; 7():254. PubMed ID: 24399926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin OX
    Jacobson LH; Chen S; Mir S; Hoyer D
    Curr Top Behav Neurosci; 2017; 33():105-136. PubMed ID: 27909987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
    Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine.
    Yao L; Ramirez AD; Roecker AJ; Fox SV; Uslaner JM; Smith SM; Hodgson R; Coleman PJ; Renger JJ; Winrow CJ; Gotter AL
    J Neurochem; 2017 Jul; 142(2):204-214. PubMed ID: 28444767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.
    Coborn JE; DePorter DP; Mavanji V; Sinton CM; Kotz CM; Billington CJ; Teske JA
    Int J Obes (Lond); 2017 Aug; 41(8):1256-1262. PubMed ID: 28392556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats.
    Gamble MC; Katsuki F; McCoy JG; Strecker RE; McKenna JT
    Neuroscience; 2021 May; 463():30-44. PubMed ID: 33737028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.
    Roch C; Bergamini G; Steiner MA; Clozel M
    Psychopharmacology (Berl); 2021 Oct; 238(10):2693-2708. PubMed ID: 34415378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily treatment with the dual orexin receptor antagonist DORA-12 during oxycodone abstinence decreases oxycodone conditioned reinstatement.
    Illenberger JM; Flores-Ramirez FJ; Pascasio G; Matzeu A; Martin-Fardon R
    Neuropharmacology; 2023 Nov; 239():109685. PubMed ID: 37579870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the dual orexin receptor antagonist DORA-22 on sleep in 5XFAD mice.
    Duncan MJ; Farlow H; Tirumalaraju C; Yun DH; Wang C; Howard JA; Sanden MN; O'Hara BF; McQuerry KJ; Bachstetter AD
    Alzheimers Dement (N Y); 2019; 5():70-80. PubMed ID: 30859123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSPH-D-18-00526: Effect of a dual orexin receptor antagonist (DORA-12) on sleep and event-related oscillations in rats exposed to ethanol vapor during adolescence.
    Ehlers CL; Benedict J; Wills D; Sanchez-Alavez M
    Psychopharmacology (Berl); 2020 Oct; 237(10):2917-2927. PubMed ID: 31659377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure.
    Winrow CJ; Tanis KQ; Reiss DR; Rigby AM; Uslaner JM; Uebele VN; Doran SM; Fox SV; Garson SL; Gotter AL; Levine DM; Roecker AJ; Coleman PJ; Koblan KS; Renger JJ
    Neuropharmacology; 2010 Jan; 58(1):185-94. PubMed ID: 19596018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition.
    Uslaner JM; Tye SJ; Eddins DM; Wang X; Fox SV; Savitz AT; Binns J; Cannon CE; Garson SL; Yao L; Hodgson R; Stevens J; Bowlby MR; Tannenbaum PL; Brunner J; Mcdonald TP; Gotter AL; Kuduk SD; Coleman PJ; Winrow CJ; Renger JJ
    Sci Transl Med; 2013 Apr; 5(179):179ra44. PubMed ID: 23552372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and development of orexin receptor antagonists as therapeutics for insomnia.
    Winrow CJ; Renger JJ
    Br J Pharmacol; 2014 Jan; 171(2):283-93. PubMed ID: 23731216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.